Business / Corporate Jul 13, 2021
Eisai pushes second Alzheimer's drug despite call to probe U.S. approval of first
by Lisa Du and Grace Huang
The U.S. Food and Drug Administration’s June approval of Aduhelm caused resignations among a panel of independent experts who said the therapy was ineffective.
